The NEJM has reported the NIH's Undiagnosed Diseases Network (UDN) study results of genetically identifying new diseases from prospectively followed persons with undiagnosed disorders.
The UDN was formed in 2014 as a network of seven clinical sites, two sequencing cores, a coordinating center, central biorepository, a metabolomics core, and a model organisms screening center. It was established to apply a multidisciplinary model in the
Dr. John Cush RheumNow
7 years 10 months ago
Vasculitis may complicate autoinflammatory Dz - in FMF (IgA vasculitis, PAN), vasculitis may occur w/ CAPS, TRAPS, HIDS, DIRA, PAPA & Behcets syndromes. Vasculitis is part of DAD2 deficiency (STING-assoc vasculopathy w/ onset in infancy-SAVI (PAN-like) https://t.co/7MKo05pOa3
Dr. John Cush RheumNow
7 years 10 months ago
Systematic review of 41 papers shows that polymyalgia rheumatica is associated with comorbidities - CVA, CAD, peripheral arterial disease, diverticular disease, hypothyroidism, but there is disagreement as to an association betw PMR and cancer. https://t.co/74rwKuixR8
Dr. John Cush RheumNow
7 years 10 months ago
Registry studies of systemic sclerosis shows that early severe GI involvement (9% at 2yrs) is associated with increase risk of inflammatory myositis (OR 4.68), telangiectasias (OR 2.45), skin progression and a >2-fold risk of death (HR 2.27) https://t.co/6e96TldL2S
Dr. John Cush RheumNow
7 years 10 months ago
Pfizer intends to do a phase 3 study of tofacitinib 5 mg bid (vs PBO) in adults with active ankylosing spondylitis ~ 240 pts in a multinational study. Previously a 16 week, phase 2 trial showed an 82% ASAS20 response in AS pts. https://t.co/u1I0Tpdtl6
The risk for cancer in systemic lupus erythematosus (SLE) patients has been inconsistently studied. A new metanalysis shows that SLE has an increased risk for 16 specific cancers and decreased risk for prostate cancer and cutaneous melanoma.
Sometimes patients withhold information from their doctors, and a new study suggests that as much as 60 - 80% of patients consciously omit information to their doctors, despite knowing this may bear on their health and well-being.
Dr. John Cush RheumNow
7 years 10 months ago
Full text overview of novel biologic and molecular targets studied or in development for SLE. https://t.co/7SGzKNm4Aa https://t.co/ki5toh6O3P
Dr. John Cush RheumNow
7 years 10 months ago
Galectin-9 is a biomarker correlating with type 1 IFN signature and correlates w/ disease activity in SLE and and antiphospholipid syndrome and may also correlate with other autoimmune Dz - Sjögren’s, systemic sclerosis & juvenile) dermatomyositis https://t.co/TfpwMAIaaI
Dr. John Cush RheumNow
7 years 10 months ago
RheumNow Podcast is Up - Can RA be Prevented? watch here https://t.co/enxuQcF0qf or listen on iTunes, Stitcher or Soundcloud https://t.co/nmK3h2ri7I https://t.co/qS33jbtaUt
Dr. John Cush RheumNow
7 years 10 months ago
The Best Rheums go to the Best Meetings - RHEUMNOW LIVE - March 22-24 2019 Great Venue =Fort Worth. Short Lectures, interactive sessions, Q&A panels, TED (like) Talks, digital, streaming and much more. You dont want to miss this meeting! https://t.co/5TVg0Frsbf
Secretary Alex Azar SecAzar
7 years 10 months ago
As we continue our efforts to reduce the high cost of prescription drugs, meetings with groups like @ArthritisFdn and @ACRheum provide important insight into the needs of patients and physicians. https://t.co/jOOK4THTQ6
Angus Worthing MD AngusWorthing
7 years 10 months ago
Bipartisan senators introduce new drug pricing bill https://t.co/mDWxPEtHhz
Dr. Jack Cush reviews the news and new journal articles from the past week on RheumNow.com:
